Lynn E. Spitler
Allergy and Immunology
450 Stanyan St
Norther California Melanoma Center St. Mary's Med Cente
San Francisco, CA 94117
Norther California Melanoma Center St. Mary's Med Cente
San Francisco, CA 94117
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 31, 2021
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Journal: Cancer
Published: June 05, 2018
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.
Journal: Oncoimmunology
Published: July 24, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 28, 2015
Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
Journal: American journal of clinical oncology
Published: January 24, 2015
Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma.
Journal: American journal of clinical oncology
Published: October 07, 2014
Showing 1-6 of 6
Last Updated: 09/26/2026